Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Blood groups, plasminogen (PLG) polymorphism  (2)
  • Advanced ovarian cancer  (1)
  • 1
    Electronic Resource
    Electronic Resource
    Plasminogen (PLG) polymorphism in northern Japanese: Confirmation of PLG*M6 allele (1989)
    Springer
    International journal of legal medicine 103 (1989), S. 43-45 
    Details
    ISSN: 1437-1596
    Keywords: Blood groups, plasminogen (PLG) polymorphism ; Plasminogen polymorphism in northern Japanese ; Blutgruppen, Plasminogen (PLG) ; Plasminogen-Polymorphismus, Nord-Japan
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine , Law
    Description / Table of Contents: Zusammenfassung Der genetische Polymorphismus des Plasminogen (PLG) wurde mit Hilfe der Isoelektrofokussierung und des Immunoblotting in einer Stichprobe von 450 nicht verwandten Personen aus der nördlichen Region Japans untersucht. Die folgende Allelfrequenzen wurden ermittelt: PLG*A =0.961, PLG*A3=0.009, PLG*M2=0.001, PLG*M5=0.016, PLG*M6= 0.001, PLG*B=0.003 and PLG*B2=0.009.
    Notes: Summary Plasminogen (PLG) phenotyping has been performed on 450 unrelated individuals from northern Japan, using wide-scale ultrathin layer polyacrylamide gel isoelectric focusing combined with immunoblotting. One common phenotype and six rare ones were observed. The rare phenotypes included the recently detected allele PLG*M6 in a new combination with PLG*M5 allele. The estimated allele frequencies for PLG*A, PLG*A3, PLG*M2, PLG*M5, PLG*M6, PLG*B, and PLG*B2 were 0.961, 0.009, 0.001, 0.016, 0.001, 0.003, and 0.009, respectively.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01255845
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Plasminogen (PLG) polymorphism in northern Japanese: Confirmation of PLG*M6 allele (1989)
    Springer
    International journal of legal medicine 103 (1989), S. 43-45 
    Details
    ISSN: 1437-1596
    Keywords: Blood groups, plasminogen (PLG) polymorphism ; Plasminogen polymorphism in northern Japanese ; Blutgruppen, Plasminogen (PLG) ; Plasminogen-Polymorphismus, Nord-Japan
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine , Law
    Description / Table of Contents: Zusammenfassung Der genetische Polymorphismus des Plasminogen (PLG) wurde mit Hilfe der Isoelektrofokussierung und des Immunoblotting in einer Stichprobe von 450 nicht verwandten Personen aus der nördlichen Region Japans untersucht. Die folgende Allelfrequenzen wurden ermittelt: PLG*A = 0.961, PLG*A3 = 0.009, PLG*M2 = 0.001, PLG*M5 = 0.016, PLG*M6 = 0.001, PLG*B = 0.003 und PLG*B2 = 0.009.
    Notes: Summary Plasminogen (PLG) phenotyping has been performed on 450 unrelated individuals from northern Japan, using wide-scale ultrathin layer polyacrylamide gel isoelectric focusing combined with immunoblotting. One common phenotype and six rare ones were observed. The rare phenotypes included the recently detected allele PLG*M6 in a new combination with PLG*M5 allele. The estimated allele frequencies for PLG*A, PLG*A3, PLG*M2, PLG*M5, PLG*M6, PLG*B, and PLG*B2 were 0.961, 0.009, 0.001, 0.016, 0.001, 0.003, and 0.009, respectively.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00203942
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Paclitaxel-cisplatin combination in advanced ovarian cancer: a phase II study (2000)
    Springer
    International journal of clinical oncology 5 (2000), S. 85-88 
    Details
    ISSN: 1437-7772
    Keywords: Key words Paclitaxel ; Cisplatin ; Advanced ovarian cancer ; First-line chemotherapy
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background. To date there have been four large randomized studies in Western countries examining the role of combining cisplatin and paclitaxel as first-line treatment for ovarian cancer. A phase II study of paclitaxel and cisplatin in Japanese patients with advanced ovarian cancer was performed to determine the objective response rate and toxicity of this regimen. Methods. Previously untreated patients with stage III or IV ovarian cancer and a good performance status were eligible. Treatment consisted of paclitaxel 180 mg/m2 administered as a 3-h intravenous (i.v.) infusion followed by cisplatin 60 mg/m2 i.v. Treatment was repeated every 3 weeks for at least four cycles. Granulocyte colony-stimulating factor (G-CSF) was not routinely used. Results. Among 26 eligible patients, there were 4 complete and 17 partial responses, for an overall response rate of 80.8% (95% confidence interval [CI], 60.6% to 93.4%). One hundred and twenty-nine treatment cycles were administered to the 26 patients. Grade 4 neutropenia was observed in 64 treatment cycles (50%) and in 23 patients (88%). Thrombocytopenia was less common. The most common nonhematologic toxicities included neurotoxicity, fatigue, arthralgia/myalgia, and nausea/emesis. Conclusion. Paclitaxel plus cisplatin is a highly active regimen in patients with advanced ovarian cancer. The toxicities of this regimen are well tolerated.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s101470050096
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...